IP Library › Granted Patent US 12,459,995
Granted Patent B2
US 12,459,995 · App. 17/285,861 · Granted Nov 4, 2025

Use of anti-FAM19A5 antibodies

Inventors: Bongcheol Kim (Seongnam-si, KR); Dong Sik Kim (Seoul, KR); Soon-Gu Kwon (Seoul, KR)
Assignee: NEURACLE SCIENCE CO., LTD.
C07K16/24A61P27/02A61K2039/505C07K2317/33C07K2317/56C07K2317/76C07K2317/92
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,459,995
App. No.
17/285,861
Granted
Nov 4, 2025
Kind
B2
Abstract

The present disclosure relates to the pharmaceutical use of antagonists (e.g., an antibody or antigen-binding portion thereof) that specifically bind to FAM19A5 to treat a retinopathy (e.g., diabetic retinopathy) and/or maculopathy (e.g., age-related macular degeneration) in a subject in need thereof.

Claims (28)

1 . A method of improving a retinal potential in a retina of a subject in need thereof comprising administering to the subject

an antibody, or an antigen-binding portion thereof, that specifically binds to a family with sequence similarity 19, member A5 (FAM19A5) protein (anti-FAM19A5 antibody);

wherein the anti-FAM19A5 antibody comprises a heavy chain CDR1, CDR2, and CDR3, and a light chain CDR1, CDR2, and CDR3,

wherein the heavy chain CDR1, CDR2, and CDR3 comprises the amino acid sequence set forth in SEQ ID NOs: 212, 213, and 16, respectively, and the light chain CDR1, CDR2, and CDR3 comprises the amino acid sequence set forth in SEQ ID NOs: 222, 225, and 224, respectively; and

wherein the subject has a disease or condition selected from a diabetic retinopathy, an age-related macular degeneration, or both.

2 . The method of claim 1 , wherein the diabetic retinopathy comprises a nonproliferative diabetic retinopathy (NPDR), a proliferative diabetic retinopathy, or both.

3 . The method of claim 1 , wherein the anti-FAM19A5 antibody comprises a heavy chain variable region (VH) comprising the amino acid sequence set forth in SEQ ID NO: 236, and a light chain variable region (VL) comprising the amino acid sequence set forth in SEQ ID NO: 245.

4 . The method of claim 1 , wherein the anti-FAM19A5 antibody comprises a Fab, Fab′, F(ab′)2, Fv, or single chain Fv (scFv).

5 . A method of treating a retinopathy and/or maculopathy in a subject in need thereof comprising administering to the subject

an antibody, or an antigen-binding portion thereof, that specifically binds to a family with sequence similarity 19, member A5 (FAM19A5) protein (anti-FAM19A5 antibody);

wherein the anti-FAM19A5 antibody comprises a heavy chain CDR1, CDR2, and CDR3, and a light chain CDR1, CDR2, and CDR3,

wherein the heavy chain CDR1, CDR2, and CDR3 comprises the amino acid sequence set forth in SEQ ID NOs: 212, 213, and 16, respectively, and the light chain CDR1, CDR2, and CDR3 comprises the amino acid sequence set forth in SEQ ID NOs: 222, 225, and 224, respectively; and

wherein: (i) the retinopathy comprises a diabetic retinopathy; (ii) the maculopathy comprises a diabetic macular edema; or (iii) both (i) and (ii).

6 . The method of claim 5 , wherein the anti-FAM19A5 antibody comprises a heavy chain variable region (VH) comprising the amino acid sequence set forth in SEQ ID NO: 236, and a light chain variable region (VL) comprising the amino acid sequence set forth in SEQ ID NO: 245.

7 . The method of claim 5 , wherein the anti-FAM19A5 antibody comprises a Fab, Fab′, F(ab′)2, Fv, or single chain Fv (scFv).

8 . The method of claim 5 , wherein the anti-FAM19A5 antibody is a chimeric antibody or a humanized antibody.

9 . The method of claim 5 , wherein the anti-FAM19A5 antibody is linked to a molecule having a second binding moiety, thereby forming a bispecific molecule.

10 . The method of claim 5 , wherein the anti-FAM19A5 antibody is linked to an agent, thereby forming an immunoconjugate.

11 . The method of claim 5 , wherein the anti-FAM19A5 antibody is administered via an intraocular administration, an intravenous administration, or both.

12 . A method of treating a macular degeneration in a subject in need thereof comprising administering to the subject

an antibody, or an antigen-binding portion thereof, that specifically binds to a family with sequence similarity 19, member A5 (FAM19A5) protein (anti-FAM19A5 antibody);

wherein the anti-FAM19A5 antibody comprises a heavy chain CDR1, CDR2, and CDR3, and a light chain CDR1, CDR2, and CDR3, and

wherein the heavy chain CDR1, CDR2, and CDR3 comprises the amino acid sequence set forth in SEQ ID NOs: 212, 213, and 16, respectively, and the light chain CDR1, CDR2, and CDR3 comprises the amino acid sequence set forth in SEQ ID NOs: 222, 225, and 224, respectively.

13 . The method of claim 12 , wherein the macular degeneration comprises an age-related macular degeneration (AMD).

14 . The method of claim 13 , wherein the AMD comprises a dry macular degeneration, a wet macular degeneration, or both.

15 . The method of claim 13 , wherein the AMD comprises (i) an early AMD, (ii) an intermediate AMD, (iii) a late or advanced AMD, or (iv) a combination thereof.

16 . The method of claim 12 , wherein the anti-FAM19A5 antibody comprises a heavy chain variable region (VH) comprising the amino acid sequence set forth in SEQ ID NO: 236, and a light chain variable region (VL) comprising the amino acid sequence set forth in SEQ ID NO: 245.

17 . The method of claim 12 , wherein the anti-FAM19A5 antibody comprises a Fab, Fab′, F(ab′)2, Fv, or single chain Fv (scFv).

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 13, 2025
From: KIM, BONGCHEOL; KIM, DONG SIK; KWON, SOON-GU
To: NEURACLE SCIENCE CO., LTD.
Reel/Frame 071412/0306 →
Continuity (2)
Provisional Application 62746194 · Oct 16, 2018
Related Publication 20210347872A1 · Nov 11, 2021
References Cited (120)
US 4044126A · Cook et al. · 1977 [cited by applicant]
US 4364923A · Cook et al. · 1982 [cited by applicant]
US 4414209A · Cook et al. · 1983 [cited by applicant]
US 5693780A · Newman et al. · 1997 [cited by applicant]
US 5709874A · Hanson et al. · 1998 [cited by applicant]
US 5759542A · Gurewich · 1998 [cited by applicant]
US 5840674A · Yatvin et al. · 1998 [cited by applicant]
US 5860957A · Jacobsen et al. · 1999 [cited by applicant]
US 5900252A · Calanchi et al. · 1999 [cited by applicant]
US 5948433A · Burton et al. · 1999 [cited by applicant]
US 5972366A · Haynes et al. · 1999 [cited by applicant]
US 5983134A · Ostrow · 1999 [cited by applicant]
US 5985307A · Hanson et al. · 1999 [cited by applicant]
US 5985317A · Venkateshwaran et al. · 1999 [cited by applicant]
US 6004534A · Langer et al. · 1999 [cited by applicant]
US 6010715A · Wick et al. · 2000 [cited by applicant]
US 6024975A · D'Angelo et al. · 2000 [cited by applicant]
US 6039975A · Shah et al. · 2000 [cited by applicant]
US 6048736A · Kosak · 2000 [cited by applicant]
US 6060082A · Chen et al. · 2000 [cited by applicant]
US 6071495A · Unger et al. · 2000 [cited by applicant]
US 6120751A · Unger · 2000 [cited by applicant]
US 6131570A · Schuster et al. · 2000 [cited by applicant]
US 6139865A · Friend et al. · 2000 [cited by applicant]
US 6167301A · Flower et al. · 2000 [cited by applicant]
US 6253872B1 · Neumann · 2001 [cited by applicant]
US 6256533B1 · Yuzhakov et al. · 2001 [cited by applicant]
US 6261595B1 · Stanley et al. · 2001 [cited by applicant]
US 6267983B1 · Fujii et al. · 2001 [cited by applicant]
US 6271359B1 · Norris et al. · 2001 [cited by applicant]
US 6274552B1 · Tamarkin et al. · 2001 [cited by applicant]
US 6316652B1 · Steliou · 2001 [cited by applicant]
US 9579398B2 · Seong et al. · 2017 [cited by applicant]
US 10640557B2 · Seong et al. · 2020 [cited by applicant]
US 11155613B2 · Kim et al. · 2021 [cited by applicant]
US 11332521B2 · Kim et al. · 2022 [cited by applicant]
US 11560425B2 · Kim et al. · 2023 [cited by applicant]
US 11618783B2 · Kim et al. · 2023 [cited by applicant]
US 11634484B2 · Kim · 2023 [cited by examiner]
US 11739141B2 · Seong et al. · 2023 [cited by applicant]
US 11746149B2 · Kim · 2023 [cited by examiner]
US 20040014194A1 · Beyer et al. · 2004 [cited by applicant]
US 20090221670A1 · Borglum et al. · 2009 [cited by applicant]
US 20120100140A1 · Reyes et al. · 2012 [cited by applicant]
US 20150118230A1 · Seong · 2015 [cited by examiner]
US 20190300599A1 · Kim · 2019 [cited by examiner]
US 20210388382A1 · Kim · 2021 [cited by examiner]
US 20220064277A1 · Kim · 2022 [cited by examiner]
US 20220144932A1 · Kim · 2022 [cited by examiner]
CN 104254343A · 2014 [cited by applicant]
CN 107019800A · 2017 [cited by applicant]
KR 20160101786A · 2016 [cited by applicant]
WO WO9712622A1 · 1997 [cited by applicant]
WO WO9817815A1 · 1998 [cited by applicant]
WO WO9817816A1 · 1998 [cited by applicant]
WO WO9818934A1 · 1998 [cited by applicant]
WO WO9931251A1 · 1999 [cited by applicant]
WO WO2013122408A1 · 2013 [cited by applicant]
WO WO2015015003A1 · 2015 [cited by examiner]
WO WO2018083538A1 · 2018 [cited by applicant]
WO WO2020079595A1 · 2020 [cited by applicant]
Liu et al., Recent Advances in Anti-cancer Protein/Peptide Delivery, Bioconjugate Chemistry, 2019, 30:305-324. (Year: 2019). [cited by examiner]
Hueso et al., ncRNAs in Therapeutics: Challenges and Limitations in Nucleic Acid-Based Drug Delivery, Int. J. Mol. Sci., 2021, 22:11596, pp. 1-15. (Year: 2021). [cited by examiner]
Yu et al., RNA Drugs and RNA Targets for Small Molecules: Principles, Progress, and Challenges, Pharmacological Reviews, 2020 , 72:862-898. (Year: 2020). [cited by examiner]
Hollevoet et al., State of play and clinical prospects of antibody gene transfer, J Transl Med 2017, 15:131, pp. 1-19. (Year: 2017). [cited by examiner]
Eisele et al., Blocking the PD-1/PD-L1 Signaling Pathway in Malignant Glioma: Current and Future Perspectives Contemporary Oncology, Aug. 2015, 7(3): 1-5. (Year: 2015). [cited by examiner]
Almagro et al., Front. Immunol. 2018; 8:1751. [cited by examiner]
Herold et. al., Sci Rep. Sep. 25, 2017;7(1):12276. [cited by examiner]
Murphy et al., Journal of Immunological Methods, vol. 463, p. 127-133, 2018. [cited by examiner]
An, Z., et al., “IgG2m4, an Engineered Antibody Isotype With Reduced Fc Function,” MAbs, 6, 572-579, Taylor & Francis, United States (Nov.-Dec. 2009). [cited by applicant]
Bird, R.E., et al., “Single-chain Antigen-binding Proteins,” Science 242(4877):423-426, Association for the Advancement of Science, United States (Oct. 1988). [cited by applicant]
Bricogne, G., “Bayesian Statistical Viewpoint on Structure Determination: Basic Concepts and Examples,” Methods in Enzymology 276:361-423, Academic Press, United States (1997). [cited by applicant]
Bricogne, G., et al., “Direct phase determination by entropy maximization and likelihood ranking: status report and perspectives,” Acta Crystallogr D. Biol. Crystallogr 49(1):37-60, Wiley Online Library, United States (… [cited by applicant]
Champe, M., et al., “Monoclonal Antibodies that Block the Activity of Leukocyte Function-Associated Antigen 1 Recognize Three Discrete Epitopes in the Inserted Domain of CD11a,” The Journal of Biological Chemistry 270 (… [cited by applicant]
Chayen, N.E., et al., “The Role of Oil in Macromolecular Crystallization,” Structure 5(10):1269-1274, Cell Press, United States (1997). [cited by applicant]
Cheung, R.C., et al., “Epitope-specific Antibody Response to the Surface Antigen of Duck Hepatitis B Virus in Infected Ducks,” Virology 176(2):546-552, Academic Press, United States (1990). [cited by applicant]
Chothia, C. and Lesk, A.M., “Canonical Structures for the Hypervariable Regions of Immunoglobulins,” Journal of Molecular Biology 196(4):901-917, Elsevier Science, United States (Aug. 1987). [cited by applicant]
Corinna Lau, et al., “Chimeric Anti-CD14 IGG2/4 Hybrid Antibodies for Therapeutic Intervention in Pig and Human Models of Inflammation,” Journal of Immunology 91(9):4769-4777, American Association of Immunologists, Unit… [cited by applicant]
Cunningham, B.C. and Wells, J.A., “High-resolution Epitope Mapping of hGH-receptor Interactions by Alanine-scanning Mutagenesis,” Science 244(4908):1081-1085, American Association for the Advancement of Science, United … [cited by applicant]
Edelman, G.M. et al., “The Covalent Structure of an Entire gammaG Immunoglobulin Molecule,” Proceedings of the National Academy of Sciences USA 63(1):78-85, National Academy of Sciences, United States (1969). [cited by applicant]
Gheorghe A., et al., “Age-Related Macular Degeneration,” Romanian Journal of Ophthalmology, 59(2):74-77, Romanian Society of Ophthalmology, Romania (2016). [cited by applicant]
Giege, R., et al., “Crystallogenesis of biological macromolecules: facts and perspectives,” Acta Crystallographica. Section D, Biological Crystallography 50(Pt4):339-350, Wiley-Blackwell, United States (1994). [cited by applicant]
Harlow, E. and Lane D., “Epitope Mapping by Competition Assay,” CSH protocols 2006(2), Cold Spring Harbor Laboratory, United States (2006). [cited by applicant]
Harmsen, M.M., et al., “Properties, Production, and Applications of Camelid Single-Domain Antibody Fragments,” Applied Microbiology and Biotechnology 77(1):13-22, Springer International, Germany (Nov. 2007). [cited by applicant]
Holz, F.G., et al., “Recent Developments in the Treatment of Age-Related Macular Degeneration,” The Journal of Clinical Investigation, 124(4):1430-1438, American Society for Clinical Investigation, United States (Apr. 2… [cited by applicant]
Huston, J.S., et al., “Protein Engineering of Antibody Binding Sites: Recovery of Specific Activity in an Anti-digoxin Single-chain Fv Analogue Produced in [cited by applicant]
International Search Report and Written Opinion for Application No. PCT/IB2019/058794, International Bureau, mailed on Jan. 22, 2020, 8 pages. [cited by applicant]
Jefferis, R., et al., “Human Immunoglobulin Allotypes: Possible Implications for Immunogenicity,” Mabs 1(4):332-338, Taylor & Francis, United States (Jul.-Aug. 2009). [cited by applicant]
Kabat, E.A & Wu, T.T., “Attempts to Locate Complementarity-Determining Residues in the Variable Positions of Light and Heavy Chains,” Annals of the New York Academy of Sciences, 190: 382-391, New York Academy of Science… [cited by applicant]
Kirkland, T.N., et al., “Analysis of the Fine Specificity and Cross-reactivity of Monoclonal Anti-lipid A Antibodies,” Journal of Microbiology 137(11):3614-3619, Microbiological Society of Korea, Korea (1986). [cited by applicant]
Kostelny, S.A., et al., “Formation of a Bispecific Antibody by the Use of Leucine Zippers,” The Journal of Immunology 148(5):1547-1553, American Association of Immunologists, United States (Mar. 1992). [cited by applicant]
Lee, R., et al., “Epidemiology of Diabetic Retinopathy, Diabetic Macular Edema and Related Vision Loss,” Eye and Vision, 2:17, BioMed Central, United Kingdom (Sep. 2015). [cited by applicant]
Lefranc, M.P., et al., “IMGT Unique Numbering for Immunoglobulin and T Cell Receptor Variable Domains and Ig Superfamily V-like Domains,” Developmental and Comparative Immunology 27(1):55-77, Elsevier Science, United St… [cited by applicant]
Lonberg, N., “Human Antibodies From Transgenic Animals,” Nature Biotechnology, 23(9):1117-1125, Nature America Publishing, United States (Sep. 2005). [cited by applicant]
McCafferty, J., et al., “Phage Antibodies: Filamentous Phage Displaying Antibody Variable Domains,” Nature 348(6301):552-554, Nature Publishing Group, United Kingdom (Dec. 1990). [cited by applicant]
McPherson, A., “Crystallization of Proteins From Polyethylene Glycol,” The Journal of Biological Chemistry 251(20):6300-6303, American Society for Biochemistry and Molecular Biology, United States (1976). [cited by applicant]
McPherson, A., “Current Approaches to Macromolecular Crystallization,” European Journal of Biochemistry 189(1):1-23, Blackwell Science Ltd, United Kingdom (1990). [cited by applicant]
Moldenhauer, G, et al., “Identity of HML-1 Antigen on Intestinal Intraepithelial T Cells and of B-ly7 Antigen on Hairy Cell Leukaemia,” Scandinavian Journal of Immunology 32(2):77-82, Blackwell Scientific Publications, … [cited by applicant]
Morel, G.A., et al., “Monoclonal Antibodies to Bovine Serum Albumin: Affinity and Specificity Determinations,” Molecular Immunology 25(1):7-15, Pergamon Press, United Kingdom (1988). [cited by applicant]
Nentwich, M.M and ULBIG,M.W., “Diabetic Retinopathy—Ocular Complications of Diabetes Mellitus,” World Journal of Diabetes, 6(3):489-499, Baishideng Publishing Group, United States (Apr. 2015). [cited by applicant]
Pennington K.L and Deangelis M.M., “Epidemiology of Age-Related Macular Degeneration (AMD): Associations With Cardiovascular Disease Phenotypes and Lipid Factors,” Eye and Vision, 3:34, BioMed Central, United Kingdom (D… [cited by applicant]
Roux, K.H., et al., “Comparisons of the Ability of Human IgG3 Hinge Mutants, IgM, IgE, and IgA2, to form Small Immune Complexes: A Role for Flexibility and Geometry,” The Journal of Immunology 161(8):4083-4090, American… [cited by applicant]
Roversi, P., et al., “Modelling Prior Distributions of Atoms for Macromolecular Refinement and Completion,” Acta Crystallographica. Section D, Biological Crystallography 56(Pt10):1316-1323, International Union of Crysta… [cited by applicant]
Schluter, A., et al., “CD31 and VEGF Are Prognostic Biomarkers in Early-Stage, but Not in Late-Stage, Laryngeal Squamous Cell Carcinoma,” BMC Cancer, 18(1):272, BioMed Central, United Kingdom (Mar. 2018). [cited by applicant]
Songsivilai, S. and Lachmann, P.J., “Bispecific Antibody: A Tool for Diagnosis and Treatment of Disease,” Clinical and Experimental Immunology 79(3):315-321, Blackwell Scientific Publications, United Kingdom (1990). [cited by applicant]
Stahli, C., et al., “Distinction of Epitopes by Monoclonal Antibodies,” Methods in Enzymology 92:242-253, Academic Press, United States (1983). [cited by applicant]
Tang, T.Y., et al., “TAFA: A Novel Secreted Family With Conserved Cysteine Residues and Restricted Expression in the Brain,” Genomics 83(4):727-734, Academic Press, United States (Apr. 2004). [cited by applicant]
Vidarsson G, et al., “Igg Subclasses and Allotypes: From Structure to Effector Functions, ” Front Immunology 5:520, Frontiers Research Foundation, Switzerland (Oct. 2014). [cited by applicant]
Yilmaz, G., et al., “Induction of Neuro-protective/regenerative Genes in Stem Cells Infiltrating Post-ischemic Brain Tissue,” Experimental & Translational Stroke Medicine, 2(11):1-10, BioMed Central, United Kingdom (May… [cited by applicant]
Virgili, G and Bini, A., “Laser Photocoagulation for Neovascular Age-Related Macular Degeneration,” The Cochrane Database of Systematic Reviews, 3:CD004763, Wiley, United Kingdom (Jul. 2007). [cited by applicant]
Wang, Y. et al., “Novel Adipokine, FAM19A5, Inhibits Neointima Formation After Injury Through Sphingosine-1-phosphate Receptor 2”, Circulation 138:48-63, Lippincott Williams & Wilkins, United States (Jul. 2018). [cited by applicant]
Ward, E.S., et al., “Binding Activities of a Repertoire of Single Immunoglobulin Variable Domains Secreted from [cited by applicant]
Wilsey, L.J. and Fortune, B., “Electroretinography in Glaucoma Diagnosis,” Current Opinion in Ophthalmology 27(2):118-124, Lippincott Williams & Wilkins, United States (Mar. 2016). [cited by applicant]
Wong, W.L., et al., “Global Prevalence of Age-related Macular Degeneration and Disease Burden Projection for 2020 and 2040: A Systematic Review and Meta-Analysis,” The Lancet. Global Health, 2(2):e106-116, Elsevier, Uni… [cited by applicant]
Wu, L., et al., “Classification of Diabetic Retinopathy and Diabetic Macular Edema,” World Journal of Diabetes, 4(6):290-294, Baishideng Publishing Group, United States (Dec. 2013). [cited by applicant]
Mitchell, P., et al., “Age-related macular degeneration,” Lancet 392(10153):1147-1159, Elsevier, Netherlands (Sep. 2018). [cited by applicant]
Saito, M., et al., “Efficacy of intravitreal aflibercept in Japanese patients with exudative age-related macular degeneration,” Jpn J Ophthalmol 61(1):74-83, Springer Japan, Japan (Jan. 2017). [cited by applicant]
Kawashima, Y., et al., “Effects of aflibercept for ranibizumab-resistant neovascular age-related macular degeneration and polypoidal choroidal vasculopathy,” Graefes Arch Clin Exp Ophthalmol 253(9):1471-1477, Springer V… [cited by applicant]
Han, K.M., et al., “Serum FAM19A5 levels: A novel biomarker for neuroinflammation and neurodegeneration in major depressive disorder,” Brain Behav Immun 87:852-859, Elsevier, Netherlands (Jul. 2020). [cited by applicant]
Huang, S., et al., “FAM19A5/TAFA5, a novel neurokine, plays a crucial role in depressive-like and spatial memory-related behaviors in mice,” Mol Psychiatry 26(6):2363-2379, Nature Portfolio, Germany (Jun. 2021). [cited by applicant]